Sign in Subscribe
Pharmaceutical industry

ParAllele BioScience Collaborates with Novartis on Coronary Artery Disease Study

Strategic Insights

— 1 min read

ParAllele BioScience, a South San Francisco-based genetic discovery company, has entered into a collaboration with Novartis Pharma AG to discover genetic variations associated with coronary artery disease. This disease, which affects 13 million people in the United States, is the leading cause of death for both men and women. The study aims to identify biomarkers that can aid in disease diagnosis and guide treatment options, as well as identify and prioritize new drug targets. ParAllele will utilize its proprietary Mismatch Repair Detection (MRD) technology to comprehensively discover novel Single Nucleotide Polymorphisms (SNPs) in candidate genes selected by Novartis.

Key Takeaways:

  • ParAllele BioScience and Novartis Pharma AG have entered into a collaboration to discover genetic variations associated with coronary artery disease.
  • The study aims to identify biomarkers for disease diagnosis and guide treatment options, as well as identify and prioritize new drug targets.
  • ParAllele will utilize its proprietary Mismatch Repair Detection (MRD) technology to discover novel Single Nucleotide Polymorphisms (SNPs) in candidate genes selected by Novartis.
  • The results of the study will be used to aid in disease diagnosis and guide treatment options for the 13 million people in the United States affected by coronary artery disease.
  • The collaboration will enable ParAllele to retain rights for diagnostic applications while Novartis will utilize the markers in drug discovery.
  • ParAllele's proprietary SNP discovery approach has resulted in two to three times more validated SNPs than are found in public or private databases, increasing the comprehensiveness of a given study.
  • Genetic variation among drug targets or genes in a disease pathway can result in variability in disease prognosis, drug response, and the incidence of side effects.

Statistics:

  • 13 million people are affected by coronary artery disease in the United States (NewsRx.com)
  • Coronary artery disease is the leading cause of death for both men and women (NewsRx.com)
  • ParAllele's proprietary SNP discovery approach has resulted in two to three times more validated SNPs than are found in public or private databases.

Sources:

  • NewsRx.com & NewsRx.net, "ParAllele BioScience Announces Collaboration with Novartis Pharma AG" (2004 NOV 1)
  • Pharmacy Business Week, "ParAllele BioScience and Novartis Collaborate on Study" (2004)
  • Pharma Business Week via NewsRx.com & NewsRx.net, "ParAllele BioScience, Novartis and Coronary Artery Disease" (2004)

Read more